SLNO Q4 2019 Earnings — Soleno Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SLNOSoleno Therapeutics, Inc.

$2B

Q4 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$7M

Net Income

-$15M

EPS (Diluted)

$-5.40

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$295,000

Balance Sheet

Total Assets

$38M

Total Liabilities

$23M

Stockholders' Equity

$15M

Cash & Equivalents

$21M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$7M	-$4M	-94.6%
Net Income	-$15M	$263,000	-5660.8%